Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
22/06/2026 12:47
BRIEF-Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg) June 22 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
CEMDISIRAN REGULATORY SUBMISSIONS ACCEPTED FOR REVIEW BY FDA AND EMA FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG)
REGENERON PHARMACEUTICALS - EUROPEAN COMMISSION DECISION ON CEMDISIRAN EXPECTED IN SECOND HALF OF 2027
REGENERON PHARMACEUTICALS - PLANS REGULATORY FILING FOR CEMDISIRAN IN JAPAN IN EARLY 2027
REGENERON PHARMACEUTICALS - FDA TO REVIEW CEMDISIRAN NDA UNDER PRIORITY REVIEW WITH TARGET ACTION DATE NOVEMBER 2026
Source text: ID:nGNX5r0zrs
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)